Point72 Asset Management
ZYNE

Point72 Asset Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Point72 Asset Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-34,196
Closed -$102K – 1289
2018
Q4 		$102K Sell
34,196
-40,804
-54% -$223K ﹤0.01% 908
2018
Q3 		$612K Buy
+75,000
New +$576K ﹤0.01% 912

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Campbell Capital Management Miami, Florida $279M AUM 49.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

Point72 Asset Management's ZYNE Position: Q1 2019 in Review

Point72 Asset Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2019, closing a stake of 34,196 shares — an estimated $102K sold.

Point72 Asset Management first reported a position in ZYNE in Q3 2018 and held it in 2 quarters. The position peaked at $612K in Q3 2018. 61 funds tracked by Wall St. Rank hold ZYNE as of Q1 2019.

  • Point72 Asset Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2019 after selling out during the quarter.
  • Point72 Asset Management sold 34,196 Zynerba Pharmaceuticals, Inc shares in Q1 2019, an estimated $102K.
  • Point72 Asset Management first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2018 and held it in 2 quarters.
  • Point72 Asset Management's Zynerba Pharmaceuticals, Inc position peaked at $612K in Q3 2018.
  • 61 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2019.

Based on Point72 Asset Management's 13F filing for Q1 2019, filed 15 May 2019.